|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
VIVUS, Inc. (VVUS) Loss Grows to $57 Million Due to Weight Loss Drug Sales Costs
2/26/2013 8:26:22 AM
Vivus Inc., which sells an FDA-approved weight loss drug called Qsymia, lost $56.7 million in the fourth quarter of 2012, up from a loss of $11.5 million a year earlier. The higher costs of selling Qsymia, along with associated general and administrative expenses, pushed up the company's loss. This latest loss pushed Vivus' accumulated deficit -- how much money it has lost or written off since it started -- to $486,146,000, close to half a billion dollars. Sales, however, which were zero in the fourth quarter a year ago, rose to $1.97 million in the most recent quarter. For the year ended December, Vivus (NASDAQ: VVUS) lost $139.9 million on sales of $2.01 million.
|
|
|
|
|
|
|
|
|
|
|